Medtronic to present new data regarding use of the MiniMed™ 780G system among broader population at the European Association for the Study of Diabetes (EASD) 60th Annual Meeting

The company will present clinical evidence in young children, pregnancy and type 2 diabetes*

Medtronic plc, the global leader in medical technology, announced it will present new data on its MiniMed™ 780G system at the upcoming European Association for the Study of Diabetes (EASD) 60th Annual Meeting in Madrid on September 9-13. The new clinical evidence on the MiniMed ™780G system will include areas where the company intends to work with global regulators towards expanding access to its diabetes technology including a lower age for those with type 1 diabetes, and type 2 diabetes.

Today the MiniMed 780G™ system is approved for use in individuals aged 7 years and above with type 1 diabetes. Maintaining stable blood glucose levels is critical for the physical and cognitive development of very young children. By automating insulin delivery, the burden of diabetes on family life, especially during the night, can also be improved.

For women with type 1 diabetes, the challenges to achieving the necessary level of glycemic control in pregnancy to avoid risks to both the mother and the baby extend to delivery and the post-partum period. Pregnant women with type 1 diabetes are advised to aim for tighter control of their glucose levels, typically targeting a range of 63-140 mg/dL (3.5-7.8 mmol/L)[1-3], to minimize the risk of high blood sugar levels, which can have adverse effects on the baby's development.

Data will also highlight the ability of the system to reduce burden at mealtimes for people living with diabetes and more real-world evidence demonstrating the ability of the MiniMed 780G™ system to help users achieve their glycemic goals.

SCIENTIFIC DATA
The following poster and oral scientific data presentations represent the work of Medtronic employees and independent investigators using Medtronic devices in their research.

- "The LENNY randomized crossover trial demonstrates the MiniMed™ 780G system is safe and effective for children aged 2-6" –oral presentation (LBA OP O2) by Prof. Tadej Battelino, MD, Head of Department of Pediatric and Adolescent Endocrinology, UMC Ljubljana, Slovenia on Friday, September 13 at 12:15 CEST (Venue: Cairo Hall)
- "Glycemic control is not affected by season in MiniMed™ 780G system users – a real-world study from Italy" – short oral discussion (850) by Emanuele Bosi, Head physician of the General Medicine, Diabetes and Endocrinology Department and Director of the Diabetes Research Institute at Ospedale San Raffaele, Italy on Wednesday, September 11 at 12:45 CEST (Venue: Station 13)
- "GLP-1 receptor agonist effects in people with type 2 diabetes using MiniMed™ advanced hybrid closed-loop therapy" – short oral discussion (775) by John Shin, Ph.D., MBA, Senior Clinical Research Director, Medtronic Diabetes on Thursday, September 12 at 12:45 CEST (Venue: Station 11)
- "Postprandial insulin strategy for improving glycemic control after a missed meal bolus in persons with type 1 Diabetes users of the Advanced Hybrid Closed Loop (AHCL) Minimed 780G™ system." – short oral discussion (781) by Prof. Bruno Grassi MD, Nutrition, Diabetes and Metabolism unit, Pontificia Universidad Católica de Chile on Thursday, September 12 at 14:00 CEST (Venue: Station 11)
- "Real-world performance of the Minimed™ 780G safe meal bolus feature" – short oral discussion (782) by Venkataramana Putcha, Principal AI Data Science Engineer, Medtronic Diabetes on Thursday, September 12 at 14:00 CEST (Venue: Station 11)
- "Advanced hybrid closed loop compared to standard insulin therapy in type 1 diabetes during delivery and early postpartum" - short oral discussion (820) by Kaat Beunen, PhD scientist at KU Leuven, on Thursday, September 12 at 12:45 CEST (Venue: Station 12)
- "Cardiopulmonary and aerobic exercise tests assessing multiple biomarkers and hormones in type 1 diabetes under different circumstances: the act-one study" –oral presentation (LBA OP O2) by Francesca De Ridder, PhD scientist at University of Antwerp, on Tuesday, September 10 at 15:45 CEST (Venue: Cairo Hall)

MEDTRONIC SPONSORED EVENTS

Medtronic Symposium: "Expanding Horizons in Insulin Therapy: Applications of MiniMed™ 780G system. Monday, September 9, from 13:30-15:00 CET (06:30-08:00 CT) (Venue: Sydney Hall and online), chaired by Prof. Dídac Mauricio, MD PhD, Director of the Department of Endocrinology & Nutrition, Hospital de la Santa Creu i Sant Pau CIBERDEM, Spain and Prof. Ohad Cohen, MD, Senior Global Medical Affairs Director, Medtronic Diabetes.

Expert	Topic
Prof. Ohad Cohen (Switzerland) MD	Meeting the needs of diverse populations
Prof. Tadej Battelino (Slovenia) MD, PhD	The MiniMed™ 780G System study in very young children with type 1 diabetes – First results from the LENNY study
Prof. Tali Cukierman-Yaffe (Israel) MD, PhD	Using MiniMed ™780G system in Pregestational Type 1 Diabetes
Dr. Pablo Mora (US) MD	The MiniMed 780G system performance in people living with type 2 diabetes requiring insulin treatment

- "Addressing the needs of all people living with type 1 diabetes", chaired by Dr. Martín Cuesta, Hospital Clínico San Carlos, Madrid, Spain and Prof. Ohad Cohen, MD, Senior Global Medical Affairs Director, Medtronic Diabetes with speakers on Thursday, September 12 from 12:15-12:45 CET (05:15-05:45 CT)
- **Exhibit Booth** featuring interactive components focused on diabetes technology, clinical outcomes and support offerings for healthcare professionals and patients. **In-Booth Presentations** will include:
    - "New generation of Smart MDI therapy," on Tuesday, September 10 at 10:30 CEST and Wednesday, September 11 at 10:30 CEST by Madison Smith, Ph.D., R.N., CDCES, R&D Senior Clinical Product Manager, Medtronic Diabetes

---

* The MiniMed™ 780G system has not been approved for use for children aged 2-6 years, pregnancy, or type 2 diabetes by the FDA or other regulatory bodies.

[1] Battelino T, Danne T, Bergenstal RM, et al. Clinical targets for continuous glucose monitoring data interpretation: recommendations from the international consensus on time in range. Diabetes Care 2019; 42: 1593–603.

[2] Benhalima K, Beunen K, Siegelaar SE, et al. Management of type 1 diabetes in pregnancy: update on lifestyle, pharmacological treatment, and novel technologies for achieving glycaemic targets. Lancet Diabetes Endocrinol 2023; 11: 490–508.

[3] ElSayed NA, Aleppo G, Aroda VR, et al. 15. Management of diabetes in pregnancy: standards of care in diabetes—2023. Diabetes Care 2023; 46 (suppl 1): S254–66.

About the Diabetes Business at Medtronic(www.medtronicdiabetes.com)
Medtronic Diabetes is on a mission to alleviate the burden of diabetes by empowering individuals to live life on their terms, with the most advanced diabetes technology and always-on support when and how they need it. We've pioneered first-of-its-kind innovations for over 40 years and are committed to designing the future of diabetes management through next-generation sensors (CGM), intelligent dosing systems, and the power of data science and AI while always putting the customer experience at the forefront.

About Medtronic
Bold thinking. Bolder actions. We are Medtronic. Medtronic plc, headquartered in Galway, Ireland, is the leading global healthcare technology company that boldly attacks the most challenging health problems facing humanity by searching out and finding solutions. Our Mission — to alleviate pain, restore health, and extend life — unites a global team of 95,000+ passionate people across more than 150 countries. Our technologies and therapies treat 70 health conditions and include cardiac devices, surgical robotics, insulin pumps, surgical tools, patient monitoring systems, and more. Powered by our diverse knowledge, insatiable curiosity, and desire to help all those who need it, we deliver innovative technologies that transform the lives of two people every second, every hour, every day. Expect more from us as we empower insight-driven care, experiences that put people first, and better outcomes for our world. In everything we do, we are engineering the extraordinary. For more information on Medtronic (NYSE:MDT), visit www.Medtronic.com and follow Medtronic on LinkedIn.

Any forward-looking statements are subject to risks and uncertainties such as those described in Medtronic's periodic reports on file with the Securities and Exchange Commission. Actual results may differ materially from anticipated results.

For more information, contact:
Ashley Patterson
Global Communications
+1-818-576-3025

Ryan Weispfenning
Investor Relations
+1-763-505-4626
